

Vipul Jairath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2918044/publications.pdf>

Version: 2024-02-01

175
papers

5,160
citations

81900

39
h-index

106344

65
g-index

179
all docs

179
docs citations

179
times ranked

5538
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a histological index for UC. <i>Gut</i> , 2017, 66, 50-58.	12.1	264
2	Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 213-224.	3.7	210
3	Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. <i>Lancet</i> , 2015, 386, 137-144.	13.7	207
4	Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology. <i>Gut</i> , 2019, 68, 776-789.	12.1	195
5	Global burden of inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 2-3.	8.1	187
6	Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 69-81.e3.	4.4	137
7	Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 354-360.	8.1	131
8	Acute severe ulcerative colitis: from pathophysiology to clinical management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 654-664.	17.8	129
9	Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit. <i>Gut</i> , 2018, 67, gutjnl-2016-313428.	12.1	122
10	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2031-2045.e11.	4.4	121
11	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1200-1210.	3.7	115
12	Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1879-1892.	4.4	101
13	Derivation and validation of a novel risk score for safe discharge after acute lower gastrointestinal bleeding: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 635-643.	8.1	99
14	Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 3-15.	3.7	97
15	The emerging role of histologic disease activity assessment in ulcerative colitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 887-898.	1.0	93
16	Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. <i>Endoscopy</i> , 2012, 44, 723-730.	1.8	84
17	Acute variceal haemorrhage in the United Kingdom: Patient characteristics, management and outcomes in a nationwide audit. <i>Digestive and Liver Disease</i> , 2014, 46, 419-426.	0.9	81
18	HALT-IT - tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 450.	1.6	79

#	ARTICLE	IF	CITATIONS
19	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 105-119.	1.3	76
20	Mortality From Acute Upper Gastrointestinal Bleeding in the United Kingdom: Does It Display a "Weekend Effect"? <i>American Journal of Gastroenterology</i> , 2011, 106, 1621-1628.	0.4	74
21	Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. <i>Trials</i> , 2014, 15, 456.	1.6	69
22	Review article: dose optimisation of infliximab for acute severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 617-630.	3.7	68
23	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 5-23.	3.7	66
24	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 129-146.	0.8	64
25	National audit of the use of surgery and radiological embolization after failed endoscopic haemostasis for non-variceal upper gastrointestinal bleeding. <i>British Journal of Surgery</i> , 2012, 99, 1672-1680.	0.3	60
26	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1233-1244.e5.	1.3	58
27	Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. <i>BMJ Open</i> , 2015, 5, e007230-e007230.	1.9	57
28	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , 2021, 160, 2291-2302.	1.3	57
29	Red blood cell transfusion is associated with increased rebleeding in patients with nonvariceal upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 316-322.	3.7	54
30	The development of a magnetic resonance imaging index for fistulising Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 516-528.	3.7	53
31	Reliability of histologic assessment in patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 940-950.	3.7	51
32	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1158-1169.	3.7	49
33	Patterns of blood component use in cirrhosis: a nationwide study. <i>Liver International</i> , 2016, 36, 522-529.	3.9	49
34	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. <i>Rheumatology and Therapy</i> , 2020, 7, 35-64.	2.3	49
35	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	4.4	48
36	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 440-449.	1.9	47

#	ARTICLE	IF	CITATIONS
37	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Gut</i> , 2019, 68, 1162-1168.	12.1	45
38	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 167-177.	1.3	44
39	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	4.4	44
40	Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2017, 112, 1658-1669.	0.4	43
41	Histologic scoring indices for evaluation of disease activity in ulcerative colitis. <i>The Cochrane Library</i> , 2017, 2017, CD011256.	2.8	42
42	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 733-745.	0.4	42
43	Why Do Mortality Rates for Nonvariceal Upper Gastrointestinal Bleeding Differ around the World? A Systematic Review of Cohort Studies. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 537-543.	1.7	41
44	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1021-1042.	3.7	41
45	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	4.4	41
46	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. <i>American Journal of Gastroenterology</i> , 2018, 113, 1197-1205.	0.4	40
47	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	2.9	40
48	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	1.3	39
49	Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. <i>Gut</i> , 2018, 67, 61-69.	12.1	34
50	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1047-1066.	3.7	33
51	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	3.7	31
52	Efficacy of Endoscopic Dilatation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2514-2522.e8.	4.4	31
53	Improving outcomes from acute upper gastrointestinal bleeding: Table 1. <i>Gut</i> , 2012, 61, 1246-1249.	12.1	29
54	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	1.0	29

#	ARTICLE	IF	CITATIONS
55	Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 364-372.	1.9	28
56	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	3.7	27
57	Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1086-1093.	3.7	27
58	Rebleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Antiplatelets or Anticoagulants. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1276-1284.e3.	4.4	27
59	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1008-1016.	3.7	27
60	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 435-445.	3.7	26
61	Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. <i>Transfusion</i> , 2011, 51, 1940-1948.	1.6	25
62	Outcome measures in clinical trials of treatments for acute severe haemorrhage. <i>Trials</i> , 2018, 19, 533.	1.6	25
63	Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1188-1194.	3.7	24
64	Thrombosis in inflammatory bowel disease: Are we tailoring prophylaxis to those most at risk?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 166-171.	1.3	23
65	Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2354-2372.	2.3	23
66	OPO2 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S001-S002.	1.3	23
67	Poor Outcomes in Hospitalized Patients With Gastrointestinal Bleeding: Impact of Baseline Risk, Bleeding Severity, and Process of Care. <i>American Journal of Gastroenterology</i> , 2014, 109, 1603-1612.	0.4	21
68	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1401-1409.	3.7	21
69	Efficient Early Drug Development for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 1056-1060.	1.3	19
70	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 246-255.	1.3	19
71	Most noninferiority trials were not designed to preserve active comparator treatment effects. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 82-89.	5.0	19
72	Reporting of randomized factorial trials was frequently inadequate. <i>Journal of Clinical Epidemiology</i> , 2020, 117, 52-59.	5.0	19

#	ARTICLE	IF	CITATIONS
73	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1121-1132.e2.	4.4	18
74	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 784-793.	3.7	18
75	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. <i>Gastroenterology</i> , 2020, 159, 2013-2018.e7.	1.3	16
76	Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 727-736.e2.	4.4	16
77	Concomitant Use of Aminosaliculates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2374-2376.e2.	4.4	15
78	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 63-70.	8.1	15
79	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 424-431.e7.	4.4	15
80	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 885-894.	0.4	15
81	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	7.3	15
82	Outcomes following restrictive or liberal red blood cell transfusion in patients with lower gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 919-925.	3.7	14
83	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. <i>The Cochrane Library</i> , 2017, 9, CD011572.	2.8	13
84	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. <i>The Cochrane Library</i> , 2021, 2021, CD013256.	2.8	13
85	Underrepresentation of Minorities and Underreporting of Race and Ethnicity in Crohn's Disease Clinical Trials. <i>Gastroenterology</i> , 2022, 162, 338-340.e2.	1.3	13
86	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 264-271.	0.4	13
87	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1108-1117.	3.7	13
88	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicilate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 114-126.	3.7	12
89	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicilate Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2555-2563.	2.3	12
90	No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 416-424.	3.7	12

#	ARTICLE	IF	CITATIONS
91	Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. <i>Trials</i> , 2019, 20, 467.	1.6	12
92	Comparison of Risk Scores for Lower Gastrointestinal Bleeding. <i>JAMA Network Open</i> , 2022, 5, e2214253.	5.9	12
93	The Overall Approach to the Management of Upper Gastrointestinal Bleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 657-670.	1.4	11
94	What is the role of histopathology in the evaluation of disease activity in Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101601.	2.4	11
95	Challenges and Opportunities in IBD Clinical Trial Design. <i>Gastroenterology</i> , 2021, 161, 400-404.	1.3	11
96	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2017, , .	2.8	10
97	No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 481-491.	3.7	10
98	Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2598-2606.	4.4	10
99	Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. <i>Journal of Clinical Epidemiology</i> , 2016, 77, 38-43.	5.0	9
100	Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study. <i>Trials</i> , 2018, 19, 265.	1.6	9
101	Comparative outcomes in patients with ulcer- vs non-ulcer-related acute upper gastrointestinal bleeding in the United Kingdom: a nationwide cohort of 4474 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 537-545.	3.7	9
102	Diagnostic Accuracy of Non-Invasive Imaging for Detection of Colonic Inflammation in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 1926.	2.6	9
103	Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. , 2022, 10, e004560.		9
104	Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020, 2020, CD012381.	2.8	8
105	Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 711-722.	3.0	8
106	The Evolution of Treatment Paradigms in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 661-677.	2.2	7
107	High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e59-e60.	1.9	7
108	Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1251-1259.	3.7	6

#	ARTICLE	IF	CITATIONS
109	Adalimumab for maintenance of remission in Crohn's disease. The Cochrane Library, 2020, 2020, CD012877.	2.8	6
110	Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata. Inflammatory Bowel Diseases, 2021, 27, e65-e65.	1.9	6
111	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, e750-e760.	4.4	6
112	Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. Alimentary Pharmacology and Therapeutics, 2022, 55, 178-190.	3.7	6
113	Study protocol: first nationwide comparative audit of acute lower gastrointestinal bleeding in the UK. BMJ Open, 2016, 6, e011752.	1.9	5
114	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. The Cochrane Library, 0, , .	2.8	5
115	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2020, 52, 1574-1582.	3.7	5
116	PWE-295...Thrombin generation is normal in cirrhotics with acute variceal haemorrhage: results from a prospective study. Gut, 2012, 61, A418-A418.	12.1	4
117	Drug-induced Lupus Associated With Vedolizumab in a Patient with Crohn's Disease. Inflammatory Bowel Diseases, 2021, 27, e47-e48.	1.9	4
118	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. Digestive Diseases and Sciences, 2022, 67, 1128-1155.	2.3	4
119	A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT. Health Technology Assessment, 2021, 25, 1-86.	2.8	4
120	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. Clinical Gastroenterology and Hepatology, 2020, , .	4.4	4
121	Risk Stratification in Cancer Patients with Acute Upper Gastrointestinal Bleeding: Comparison of Glasgow-Blatchford, Rockall and AIMS65, and Development of a New Scoring System. Clinical Endoscopy, 2022, , .	1.5	4
122	Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials. Inflammatory Bowel Diseases, 2022, 28, 1293-1295.	1.9	4
123	The Clinical Significance of Eosinophils in Ulcerative Colitis: A Systematic Review. Journal of Crohn's and Colitis, 2022, 16, 1321-1334.	1.3	4
124	RESTRICTIVE VERSUS LIBERAL BLOOD TRANSFUSION FOR ACUTE UPPER GASTROINTESTINAL BLEEDING (TRIGGER): PRAGMATIC, CLUSTER RANDOMISED, FEASIBILITY TRIAL. Emergency Medicine Journal, 2014, 31, 780.1-780.	1.0	3
125	Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. Journal of Immunological Methods, 2018, 459, 50-54.	1.4	3
126	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Alimentary Pharmacology and Therapeutics, 2019, 49, 364-374.	3.7	3

#	ARTICLE	IF	CITATIONS
127	The Impact of Multidisciplinary Conferences on Treatment Plans for Patients With Inflammatory Bowel Disease in a Tertiary Canadian Centre. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 284-289.	0.3	3
128	Mesenchymal stromal cells (MSC) for treating immune-mediated inflammation post-transplantation and in autoimmunity. <i>The Cochrane Library</i> , 2012, , .	2.8	2
129	PWE-294â€¦.Microparticle dependent procoagulant activity and thrombin generation is increased in patients with cirrhosis induced coagulopathy. <i>Gut</i> , 2012, 61, A417.2-A417.	12.1	2
130	OC-069â€¦.Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic. <i>Gut</i> , 2012, 61, A30.1-A30.	12.1	2
131	Thrombelastographyâ€™guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. <i>Hepatology</i> , 2016, 64, 682-683.	7.3	2
132	Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives. <i>The Cochrane Library</i> , 2016, , .	2.8	2
133	Infliximab for induction of remission in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	2.8	2
134	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	2.8	2
135	P473 Contrasting the use of 5-ASA in patients with Ulcerative Colitis and Crohn's Disease: A cross-sectional analysis at a tertiary care IBD clinic. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S343-S343.	1.3	2
136	Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (<sc>EOE</sc>â€™<sc>HSS</sc>)â€™an important first step. Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1714-1715.	3.7	2
137	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 442-461.	0.8	2
138	Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e98-e98.	1.9	2
139	Vedolizumab-Induced Endoscopic and Histologic Improvement in Gastric Menetrierâ€™s Disease in a Patient With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e132-e133.	1.9	2
140	No Benefit of Continuing 5-Aminosalicylates in Patients with Crohnâ€™s Disease Treated with Anti-metabolite Therapy. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3115-3123.	2.3	2
141	The case for universal access to tranexamic acid. <i>ISBT Science Series</i> , 2012, 7, 173-176.	1.1	1
142	PTU-185â€¦.Update On The Halt-it Trial Progress: Tranexamic Acid For The Treatment Of Gastrointestinal Haemorrhage â€™ An International, Randomised, Double Blind Placebo Controlled Trial. <i>Gut</i> , 2014, 63, A120.1-A120.	12.1	1
143	Extending evidence for the use of tranexamic acid from traumatic haemorrhage to other patients with major bleeding: do we need more than one haemorrhage protocol? The case of gastrointestinal bleeding. <i>Transfusion Medicine</i> , 2015, 25, 198-200.	1.1	1
144	Oral janus kinase inhibitors for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016, , .	2.8	1

#	ARTICLE	IF	CITATIONS
145	Editorial: the impact of the placebo effect in Crohn's disease – author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1472-1472.	3.7	1
146	Letter: dose optimising infliximab in acute severe ulcerative colitis – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1170-1171.	3.7	1
147	Letter: pre-operative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 467-468.	3.7	1
148	Editorial: histologic normalisation in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 399-401.	3.7	1
149	Vedolizumab for the treatment of Non-Inflammatory Bowel Disease Related Enteropathy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	1
150	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 608.	0.8	1
151	Design of Clinical Trials for Mild to Moderate Crohn's Disease. <i>Gastroenterology</i> , 2022, , .	1.3	1
152	OC-023 – Can we predict length of stay in patients admitted with acute upper gastrointestinal bleeding?. <i>Gut</i> , 2010, 59, A10.1-A10.	12.1	0
153	PTH-020 – Acute upper gastrointestinal bleeding: why do patients die?. <i>Gut</i> , 2010, 59, A130.2-A131.	12.1	0
154	PTH-019 – Mortality from acute upper gastro-intestinal bleeding in the UK: does it display a weekend effect?. <i>Gut</i> , 2010, 59, A130.1-A130.	12.1	0
155	PWE-184 – Prevalence, management and outcomes of patients with coagulopathy following acute non-variceal upper gastrointestinal bleeding. <i>Gut</i> , 2012, 61, A371.1-A371.	12.1	0
156	OC-053 – Results Of The Uk Multi-regional Audit Of Blood Component Use In Cirrhosis. <i>Gut</i> , 2014, 63, A26.1-A26.	12.1	0
157	New oral anticoagulants in patients with atrial fibrillation. <i>Lancet, The</i> , 2014, 384, 24.	13.7	0
158	Is Treatment of Moderate Thrombocytopenia Indicated for Patients With HCV Infection and Cirrhosis?. <i>Gastroenterology</i> , 2014, 147, 254.	1.3	0
159	Treatment Targets in Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 151, 1030-1032.	1.3	0
160	Editorial: gut selective immunosuppression – is it a double edged sword? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 374-374.	3.7	0
161	Editorial: faecal microbiota transplantation for ulcerative colitis – not quite there yet? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 631-632.	3.7	0
162	Editorial: aminosalicylates in Crohn's disease – prevalence, risks, costs and time to reassess? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 489-489.	3.7	0

#	ARTICLE	IF	CITATIONS
163	Letter: immunogenicity of anti-TNF in elderly IBD patients”authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 337-337.	3.7	0
164	Editorial: evolving histological assessment of NASH. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1245-1246.	3.7	0
165	Editorial: combination immunosuppressive therapy to treat Crohn’s disease “ ready for all age groups? Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1529-1529.	3.7	0
166	Editorial: assessing histological disease activity in Crohn’s disease-a call for standardisation of mucosal biopsy location. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 104-105.	3.7	0
167	Editorial: blood transfusion for lower gastrointestinal bleeding-authors’™ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 957-957.	3.7	0
168	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. Gastroenterology, 2021, 161, 778-784.	1.3	0
169	P457 Long-term cumulative safety of ustekinumab in bionative patients with Crohn’s Disease and Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i434-i435.	1.3	0
170	Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn’s Disease: Systematic Review and Meta-Regression. Inflammatory Bowel Diseases, 2022, , .	1.9	0
171	Editorial: use of intestinal ultrasound in the scoring of Crohn’s disease activity in clinical trials “ is it ready for prime time yet? Authors’™ reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 948-949.	3.7	0
172	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis”authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 957-958.	3.7	0
173	Editorial: standardising inclusion and outcome criteria for pouchitis”a fragile consensus perhaps but a first step in the right direction. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1149-1150.	3.7	0
174	Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.. Gastroenterology and Hepatology, 2022, 18, 14-27.	0.1	0
175	Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. Inflammatory Bowel Diseases, 0, , .	1.9	0